Alliance Pharma Regulatory News (APH)

19 Sep 2005 07:02

Alliance Pharma PLC19 September 2005 For Immediate Release 19 September 2005 ALLIANCE PHARMA PLC ("Alliance" or "the Company") Appointment of Regulatory Affairs Director Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,is pleased to announce the following senior management positions. Dr Veronica Farrell-Lecomte has joined Alliance Pharma as Director of RegulatoryAffairs. This appointment boosts the resources behind Alliance's proprietarydevelopment projects, which are currently going through their clinicaldevelopment programmes. Its two in-house development programmes are PosidormTM,a surge-sustained formulation of melatonin for use in sleep disorders andIsprelorTM, an intra-vaginal formulation of misoprostol for the induction oflabour. Veronica has a PhD in molecular biology and immunology from Universite JosephFourier, Grenoble. Veronica's career to date spans more than twenty years ofresearch, clinical project management, regulatory assessment and regulatorymanagement for organisations such as the UK Central Veterinary Laboratory, theUK Department of Health, the Organisation for Economic Co-operation andDevelopment, Aventis Pharma, Orphan Europe and a Hoffman La Roche development atthe Universitatsklinikum, Leipzig. Sam Madden, previously Director of Regulatory Affairs, now takes on the new roleof Director of Acquisitions Integration, to plan and implement the transfer ofacquired brands into Alliance's operations. Commenting on the news, John Dawson, Alliance Pharma's Chief Executive, said: "I am very pleased to welcome Veronica into the Alliance Pharma team. Veronicabrings a wealth of regulatory, clinical development and project managementexperience to the company and will play a key role in our important clinicaldevelopment programmes. Both Posidorm and Isprelor, are important elements ingenerating long-term shareholder value in the company. Additionally thefocussed resource now applied to the integration of brand acquisitions gives anextra boost to that equally important source of growth." For further information:Alliance Pharma plc + 44 (0) 1249 466966John Dawson, Chief ExecutiveMaddy Scott, Finance Directorwww.alliancepharma.co.uk Buchanan Communications + 44 (0) 20 7466 5000Mark Court/Lisa Baderoon/Rebecca Skye Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed emerging specialitypharmaceutical company based in Chippenham, Wiltshire, UK. The company has astrong track record of acquiring the rights to established niche brands andowns, or shares, the rights to 30 branded pharmaceutical products and continuesto explore opportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to pharmaceutical wholesalers whichservice both hospital and retail pharmacies with their prescriptionrequirements. Alliance Pharma is also developing novel products for sleep disorders and theinduction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange